Skip to main content
Top

06-11-2023 | NSCLC | Panel Discussion | Article | F. Hoffmann-La Roche Ltd.

Panel discussion: Recent advances in early and advanced stage non-small cell lung cancer (NSCLC) presented at ESMO 2023

print
PRINT
insite
SEARCH

In this engaging panel discussion, renowned experts in non-small cell lung cancer, Dr. Luis Paz-Ares, Prof. Solange Peters and Dr. Marina Garassino provide their insights on the latest findings from the following pivotal phase III trials: ALINA, CheckMate-77T, LIBRETTO-431, and MARIPOSA-1 and -2 presented at ESMO 2023.

Presentation date: Tuesday 24th October 2023

Speakers

  • Dr. Luis Paz-Ares
    University Hospital October 12, Madrid, Spain. Read more
  • Prof. Solange Peters 
    University Hospital of Lausanne, Lausanne, Switzerland. Read more
  • Dr. Marina Garassino 
    University of Chicago, Illinois, USA. Read more

Speaker disclosures

Dr. Luis Paz-Ares

  • Speaker fees: AZ, Beigene, BMS, Daichii, Lilly, Medscape, MSD, PER, Pharmamar, Roche.
  • Board member: Altum sequencing, Genomica, Stab Therapeutics.
  • Advisory boards: Amgen, AZ, Bayer, Beigene, BMS, Daichii, GSK, Janssen, Lilly, Medscape, Merck Serono, Mirati, MSD, Novartis, PER, Pfizer, Pharmamar, Roche, Sanofi, Takeda.
  • Other: Altum sequencing, Genomica, ONCOSUR.
  • Personal: Altum sequencing, Amgen, AZ, Bayer, Beigene, BMS, Daichii, Genomica, GSK, Janssen, Lilly, Medscape, Merck Serono, Mirati, MSD, Novartis, PER, Pfizer, Pharmamar, Roche, Sanofi, Takeda, Stab Therapeutics, Amgen.
  • Institutional: Alkermes, AZ, BMS, Daiichi Sankyo, Janssen-cilag international NV, Lilly, Merck Sharp & Dohme corp, Novartis, Pfizer, Pharmamar, Roche, Sanofi, Takeda, Tesaro.
  • Coordinating PI: Alkermes, Amgen, AZ, BMS, Daiichi Sankyo, Janssen-cilag international NV, Lilly, Merck Sharp & Dohme corp, Novartis, Pfizer, Pharmamar, Roche, Sanofi, Takeda, Tesaro.
  • Financial interest: Alkermes, Amgen, AZ, BMS, Daiichi Sankyo, Janssen-cilag international NV, Lilly, Merck Sharp & Dohme corp, Novartis, Pfizer, Pharmamar, Roche, Sanofi, Takeda, Tesaro.

Prof. Solange Peters

  • Consultation / Advisory role: AbbVie, Amgen, Arcus, AstraZeneca, Bayer, Beigene, BerGenBio, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F-Star, Fishawack, Foundation Medicine, Genzyme, Gilead, GSK, Hutchmed, Illumina, Incyte, Ipsen, iTeos, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Mirati, Nykode Therapeutics, Novartis, Novocure, Pharma Mar, Promontory Therapeutics, Pfizer, Regeneron, Roche/Genentech, Sanofi, Seattle Genetics, Takeda.
  • Board of Director position: Galenica.
  • Talk in a company’s organized public event: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Foundation Medicine, GSK, Illumina, Ipsen, Merck Sharp and Dohme, Mirati, Novartis, Pfizer, Roche/Genentech, Sanofi, Takeda.
  • Receipt of grants/research supports: Principal investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, Arcus, AstraZeneca, Beigene, Bristol-Myers Squibb, GSK, iTeos, Merck Sharp and Dohme, Mirati, Pharma Mar, Promontory Therapeutics, Roche/Genentech, Seattle Genetics.

Dr. Marina Garassino

  • Honoraria: MSD Oncology, AstraZeneca/MedImmune, GlaxoSmithKline, Takeda, Roche, Bristol-Myers Squibb, Daiichi Sankyo/AstraZeneca, Regeneron, Pfizer, Blueprint Pharmaceutic, Novartis, Sanofi/Aventis, Medscape.
  • Consultancy or Advisory role: Bristol-Myers Squibb, MSD, AstraZeneca, Novartis, Takeda, Roche, Sanofi-Aventis, Celgene, Daiichi Sankyo, Pfizer, Seattle Genetics, Eli Lilly, GlaxoSmithKline, Bayer Healthcare Pharmaceuticals, Blueprint Medicines, Janssen, Regeneron, Bayer, Abbvie, Mirati, Merck, Boehringer Ingelheim, Blueprint Medicines, Abion.
  • Speakers' Bureau: AstraZeneca, MSD Oncology, Merck, Mirati, Daiichi Sankyo/AstraZeneca.
  • Research Funding: Bristol-Myers Squibb, MSD, Roche/Genentech, AstraZeneca/MedImmune, AstraZeneca, Pfizer, GlaxoSmithKline, Novartis, Merck, Incyte, Takeda, Spectrum Pharmaceuticals, Blueprint Medicines, Eli Lilly, AstraZeneca, Ipsen, Janssen, Exelixis, MedImmune, Sanofi, Amgen.
  • Travel, Accommodations, Expenses: Pfizer, Roche, AstraZeneca.

Financial disclosure

This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Disclaimer

Any information provided and opinions expressed do not necessarily reflect the views of Springer Medizin GmbH. Springer Medizin GmbH and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.

Related topics

Test your knowledge with Case-Based Clinical Insights

Oncology and Hematology Cases

45/♀ with increasing weakness, loss of appetite, diarrhoea and oedema – Case 29

A 45-year-old female patient complains that she has been getting weaker and weaker for several months. She has no appetite and suffers from diarrhoea. Immunofixation shows monoclonal lambda light chains in the serum. What is your tentative diagnosis?

48/♀ with increasing spontaneous haematomas all over her body – Case 37

A 48-year-old female patient feels listless and reports petechiae occurred for the first time. In the last 3 days, she had reportedly developed severe toothache and fever. The blood count shows severe pancytopenia. What are your first steps?

49/♀ with lymphoedema of the arm in condition of metastasised triple-negative breast carcinoma – Case 43

The 49-year-old female patient presents with significant swelling of the right arm. She reports having been diagnosed with breast cancer 1½ years ago, followed by surgical removal of the tumour. She had then received chemotherapy and irradiation. How do you proceed?

53/♂ with movement-dependent pain in the left anterior pelvis and bloody urine – Case 39

A 53-year-old man complains of increasing pain in the left anterior pelvis, which is described as movement-dependent with radiation into the left lower extremity. For several months, he had noticed bloody urine from time to time without pain during micturition. What are your suspicions?